Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of capecitabine plus oxaliplatin for advanced small bowel adenocarcinoma
jRCTs041180011Phase 2Completed
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in small bowel adenocarcinoma (SBA). Primary endpoint: 1-year progression-free survival rate. Started Jul 2020; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on jRCTs041180011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180011.